---
title: "✨ December Newsletter: What’s New & What’s Coming!"
---

The South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) Symposium are just around the corner, and you won’t want to miss them.

| View in browser Decemmber 2024 The South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) Symposium are just around the corner, and you won’t want to miss them. Register now for these must-attend events to take the next step in elevating your career and expanding your expertise. Led by the foremost experts in medical and aesthetic dermatology, these events are packed with unparalleled insights and cutting-edge content, and each year we continue to raise the bar.   Don’t forget—when you register for SBS, you automatically gain complimentary access to MOPD, which means twice the education, networking, and value at no extra cost! We’ve been busy creating insightful content and are thrilled to share a lineup of new podcasts now available on our DermDocs page! Epidermolysis Bullosa This two-part series features leading experts Joyce Teng, MD, PhD, and Michael Lavery, MD, as they delve into the complexities of epidermolysis bullosa (EB) and its profound impact on patients’ lives. Explore existing gaps and challenges in managing EB and discover the best approaches for assessing severity and subtypes to guide treatment. IL-13 Inhibition for Treatment of Prurigo Nodularis In our second episode of this series, "IL-31 Mechanism of Action and Clinical Implications," dermatologist and neuroscientist Sarina Elmariah, MD, PhD, MPH, and Shawn G. Kwatra, MD, discuss the role of IL-31 inhibitors like nemolizumab in managing prurigo nodularis. Tune in for insights into its mechanism of action, clinical efficacy, prescribing strategies, and patient selection tips. Program on JAK Inhibitors for Atopic Dermatitis The long-awaited sixth episode in this series, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis," is finally here! Christopher G. Bunick, MD, PhD, and Beth Sweney, PA-C, tackle treatment challenges in atopic dermatitis, therapeutic inertia, and provide comparative insights on upadacitinib and dupilumab, along with strategies for transitioning patients to systemic therapies. You can also tune in to these latest episodes on any of our other platforms: Featured Articles FDA Approves BIMZELEX for Moderate-to-Severe Hidradenitis Suppurativa FDA Grants Rare Pediatric Disease Designation for BPGbio’s BPM31510T for EB Topical Corticosteroid Phobia is Prevalent Among Patients with Chronic Hand Eczema Featured Blog Happy Holidays As we reflect on another year of remarkable growth and innovation, we extend our heartfelt wishes to our incredible community of medical and aesthetic dermatology professionals. May this holiday season bring you joy, inspiration, and renewed energy for the year ahead. LiVDerm, 1801 N Military Trl, Ste 110, Boca Raton, FL 33431-1810, United States, 561-893-8625 Unsubscribe Manage preferences |
| --- |